Clinical Trials Sponsored by Timmune Biotech Inc.

Total 444 results

Timmune Biotech Inc.

Unknown

Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell Therapy

Non-hodgkin Lymphoma,B Cell

China
Timmune Biotech Inc.

Unknown

Treatment of Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy

Non-Hodgkin Lymphoma

China
Noile-Immune Biotech, Inc

Recruiting

Study of NIB101 in Participants With Advanced Solid Tumors

Solid Tumor

Japan
Timmune Biotech Inc.
Hunan Provincial People's Hospital

Unknown

Treatment of Hematological Malignancy With Novel CAR-T Cells.

Multiple Myeloma | B-cell Acute Lymphoblastic Leukemia | B-cell Non Hodgkin Lymphoma

China
Timmune Biotech Inc.
Hunan Provincial People's Hospital

Unknown

Treatment of Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy

Leukemia | Non-Hodgkin Lymphoma of Intestine

China
Timmune Biotech Inc.
Hunan Provincial People's Hospital

Unknown

Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19 (Trident19-H)

Non-hodgkin Lymphoma,B Cell

China
Theratocular Biotek Co.

Recruiting

A Study to Investigate the Effect on Central Macular Thickness of Treatment With MG-O-1002 Eye Drops in Participants Aged Over 45 With Neovascular Age-related Macular Degeneration (nAMD)

Age-Related Macular Degeneration

Thailand
Aimmune Therapeutics, Inc.

Completed

Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)

Peanut Allergy

United States, Canada, Spain, Netherlands, Germany, United Kingdom, Ireland, Sweden, France, Italy
Aimmune Therapeutics, Inc.

Terminated

Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy

Hen Egg Allergy

United States
Aimmune Therapeutics, Inc.

Completed

Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES) (RAMSES)

Peanut Allergy

United States, Canada
Aimmune Therapeutics, Inc.

Terminated

Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents

Peanut Allergy

Spain
Aimmune Therapeutics, Inc.

Completed

Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT (ARC001)

Peanut Allergy

United States
Aimmune Therapeutics, Inc.

Completed

Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On Study

Peanut Allergy

United States
Aimmune Therapeutics, Inc.

Completed

AR101 Real-World Open-Label Extension Study

Peanut Allergy

United States, Canada
Aimmune Therapeutics, Inc.

Completed

ARTEMIS Peanut Allergy In Children (ARTEMIS)

Peanut Allergy

United Kingdom, Italy, France, Germany, Ireland, Spain, Sweden
Aimmune Therapeutics, Inc.

Completed

Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON)

Peanut Allergy

United States, United Kingdom, France, Germany
Aimmune Therapeutics, Inc.

Completed

Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) (PALISADE)

Peanut Allergy

United States, Spain, Ireland, Netherlands, Canada, United Kingdom, Germany, Denmark, Italy, Sweden
Aimmune Therapeutics, Inc.

Completed

PALISADE Follow-on Study (ARC004)

Peanut Allergy

United States, Spain, Netherlands, Italy, Canada, Germany, Ireland, Sweden, United Kingdom
Immune Biosolutions Inc

Completed

Study in Adults to Assess the Safety and Efficacy of Inhaled IBIO123, for Post-exposure Prophylaxis of COVID-19

COVID-19

South Africa, Ukraine
Intervene Immune, Inc.

Recruiting

Thymus Regeneration, Immunorestoration, and Insulin Mitigation Extension Trial (TRIIM-X)

Immunosenescence | Epigenetic Aging

United States
Immune Biosolutions Inc

Completed

Phase 1/2 Study to Evaluate the Efficacy and Safety of Inhaled IBIO123 in Participants With Mild to Moderate COVID-19 Illness

COVID-19

South Africa, Brazil
Immune Biosolutions Inc

Completed

Phase 1&2 Study to Evaluate the Safety & Efficacy of Inhaled IBIO123 in Severe COVID-19 Illness

COVID-19

Ukraine, South Africa
Altimmune, Inc.

Completed

Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)

Healthy Volunteers

United States
Altimmune, Inc.

Completed

ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)

Type 2 Diabetes

United States
Altimmune, Inc.

Completed

Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)

Non-Alcoholic Fatty Liver Disease

United States
Altimmune, Inc.

Completed

ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)

Non-Alcoholic Fatty Liver Disease

United States
Altimmune, Inc.

Completed

ALT-801 in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability

NASH - Nonalcoholic Steatohepatitis

Australia
Altimmune, Inc.

Completed

Study of the Safety and Immunogenicity of NasoVAX Extension

Influenza

United States
Altimmune, Inc.

Completed

Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B

Hepatitis B

Korea, Republic of, United Kingdom
Altimmune, Inc.

Unknown

NasoShield Study of Safety and Immunogenicity (NasoShield)

Healthy Volunteers

United States
Altimmune, Inc.

Active, not recruiting

HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)

Hepatitis B, Chronic

Spain, United Kingdom, Canada, United States, Germany
Altimmune, Inc.

Completed

ALT-801 DDI Study in Healthy Volunteers

NASH - Nonalcoholic Steatohepatitis

Australia
Altimmune, Inc.

Terminated

NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)

Coronavirus Infection

United States
Altimmune, Inc.

Recruiting

Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) (IMPACT Trial) (IMPACT)

Non-Alcoholic Steatohepatitis (NASH)

Australia, United States, Puerto Rico
Altimmune, Inc.

Completed

Efficacy and Safety of ALT-801 in the Treatment of Obesity

Obesity/Overweight

United States
Altimmune, Inc.

Completed

Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX

Influenza

United States
Altimmune, Inc.

Completed

Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.

Influenza A Subtype H5N1 Infection

United States
Timmune Biotech Inc.
The Second Affiliated Hospital of Hainan Medical University; Hainan Cancer...

Unknown

Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy

Malignant Melanoma

China
VivaVision Biotech, Inc

Recruiting

Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery

Inflammation

United States
Krystal Biotech, Inc.

Recruiting

A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency (Serpentine-1)

Alpha 1-Antitrypsin Deficiency

United States
Krystal Biotech, Inc.

Recruiting

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

Cancer | Carcinoma, Squamous Cell | Carcinoma, Basal Cell | Osteosarcoma | Cutaneous Melanoma | Melanoma Stage IV | Melanoma Stage III

United States
Krystal Biotech, Inc.

Not yet recruiting

Topical KB105 for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)

Autosomal Recessive Ichthyosis

United States
Krystal Biotech, Inc.

Recruiting

Long-Term Follow-up Protocol

Dystrophic Epidermolysis Bullosa | Recessive Dystrophic Epidermolysis Bullosa | Dominant Dystrophic Epidermolysis Bullosa

United States
Johnpro Biotech, Inc.

Recruiting

Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM

Glioblastoma

Taiwan
Krystal Biotech, Inc.

Completed

A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa

Dystrophic Epidermolysis Bullosa | Recessive Dystrophic Epidermolysis Bullosa | Dominant Dystrophic Epidermolysis Bullosa | DEB - Dystrophic Epidermolysis Bullosa

United States
Janssen Biotech, Inc.

Active, not recruiting

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease (DEVELOP)

Inflammatory Bowel Diseases | Crohn's Disease | Ulcerative Colitis | Indeterminate Colitis

United States, Canada
NKGen Biotech, Inc.

Active, not recruiting

Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy

Solid Tumor | Metastatic Cancer | Advanced Solid Tumor | Advanced Cancer | Solid Tumor, Adult | Refractory Cancer | Recurrent Cancer | Pathologically Confirmed Cancer Refractory to Conventional Therapy

United States
NKGen Biotech, Inc.

Terminated

Safety of SNK01 in Subjects With Alzheimer's Disease (ASK-AD) (ASK-AD)

Alzheimer Disease | Neuro-Degenerative Disease

Mexico
Maxigen Biotech Inc.

Completed

The Clinical Trial of Difference Between Formaderm Lidocaine and Formaderm Dermal Filler Injection

Lidocaine | Hyaluronic Acid | Dermal Fillers

Taiwan
Maxigen Biotech Inc.

Completed

ArtiAid® Plus for Knee Osteoarthritis: A Post-market Study

Hyaluronic Acid

Taiwan

Clinical Trials Sponsored by Timmune Biotech Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations